{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-008740","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.994775+00:00","generated_at":"2026-06-13T19:07:12.425153+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alzamend Neuro announces positive Phase IIA results for AL001; identifies MTD without need for lithium TDM","bullets":["Phase IIA multiple ascending dose study identified MTD of lithium carbonate equivalent 240 mg TID, unlikely to require lithium TDM.","Company plans two Phase II trials for mild-to-moderate Alzheimer's, initiated by Q1 2024.","Plans to file INDs for bipolar disorder, major depressive disorder, and PTSD by end of 2023.","CEO states data supports AL001 as next-gen lithium therapy without TDM."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-008740","json":"https://secwatch.observer/filing/0001214659-23-008740.json","markdown":"https://secwatch.observer/filing/0001214659-23-008740.md","text":"https://secwatch.observer/filing/0001214659-23-008740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923008740/0001214659-23-008740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923008740/z6212308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:07:12.425153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}